FHND-5071, a novel RET kinase inhibitor with promising preclinical metabolism and PK characteristics

Sep. 29, 2023

Researchers from Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. and affiliated organizations have published preclinical data for the novel rearranged during transfection (RET) kinase inhibitor, FHND-5071.

BioWorld Science Cancer

Today's news in brief

BioWorld

BioWorld briefs for Dec. 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 4, 2025.

Illustration of chromosome unraveling down to the DNA

First phase of synthetic human genome project successfully completes

BioWorld

The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

Laigo raises €11.5M seed money for targeted protein degradation

BioWorld Science

Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...